Overall Conclusion
Overall Conclusion
Embedded Files
This consensus report reflects the expert opinion that Safinamide represents a valuable therapeutic option for the advanced management of Parkinson's disease. The value of this approach lies in its ability to offer comprehensive and safe treatment that optimizes control in patients with motor and non-motor fluctuations. Its specific function in the management of pain at doses of 100 mg, as well as its favorable safety profile, particularly with respect to sleep and neuropsychiatric effects, serve to solidify its position as a strategic instrument within the contemporary neurological practice.
Explanatory note: The following report summarizes the perspectives, comments, and opinions expressed, as well as those reflected in the working matrices, by the panel of specialists during the "I Experts Meeting: Safinamide and Quality of Life (Evidence/Local Experiences)” held in Cartagena, Colombia, on September 13, 2025.
Report abuse